Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Schepisi

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer careVincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancerVincenza Conteduca, Elena Castro, Daniel Wetterskog, et al.
European Urology Oncology|June 3, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter ExperienceGiuseppina Bruno, Maria Iole Natalicchio, Marianna Garofoli, et al.
Oncotarget|November 9, 2016
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewFrancesco Jacopo Romano, Sabrina Rossetti, Vincenza Conteduca, et al.
European Urology|February 19, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerVincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Prostate Cancer and Prostatic Diseases|February 12, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer careVincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2019
Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancerVincenza Conteduca, Elena Castro, Daniel Wetterskog, et al.
European Urology Oncology|June 3, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter ExperienceGiuseppina Bruno, Maria Iole Natalicchio, Marianna Garofoli, et al.
Oncotarget|November 9, 2016
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a reviewFrancesco Jacopo Romano, Sabrina Rossetti, Vincenza Conteduca, et al.
European Urology|February 19, 2019
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate CancerVincenza Conteduca, Anuradha Jayaram, Nuria Romero-Laorden, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Pageof 7